Chronic Lymphocytic Leukemia CLL Prognostic Panel Test sale cost 4210 AED
B-Cell Rearrangement Detection Test sale cost 3300 AED B-Cell Rearrangement Detection Test Cost 5,000 د.إ Original price was: 5,000 د.إ.3,300 د.إCurrent price is: 3,300 د.إ.
Breast Cancer ER PR HER-2 Ki-67 Test sale cost 3600 AED Breast Cancer ER PR HER-2 Ki-67 Test Cost 4,000 د.إ Original price was: 4,000 د.إ.3,600 د.إCurrent price is: 3,600 د.إ.
Sale!

Chronic Lymphocytic Leukemia CLL Prognostic Panel Test Cost

Original price was: 4,680 د.إ.Current price is: 4,210 د.إ.

-10%

The Chronic Lymphocytic Leukemia (CLL) Prognostic Panel Test is a comprehensive diagnostic tool designed to assess the risk and progression of CLL, a type of cancer that affects the blood and bone marrow. This test is particularly crucial for individuals diagnosed with CLL as it helps in determining the aggressiveness of the disease and guides healthcare professionals in tailoring the most effective treatment strategies for the patient.

Performed at DNA Labs UAE, a leading facility in genetic and molecular diagnostics, the test involves analyzing specific genetic markers and mutations associated with CLL. These include chromosomal abnormalities, gene mutations, and expression levels of certain proteins that influence the behavior of the disease. By evaluating these parameters, the test provides valuable insights into the prognosis of CLL, helping predict the patient’s response to treatment and potential survival outcomes.

The cost of the CLL Prognostic Panel Test at DNA Labs UAE is 4210 AED. This investment can be invaluable for patients and their families, offering them a clearer understanding of the disease’s trajectory and enabling informed decisions regarding treatment options. DNA Labs UAE employs cutting-edge technology and expertise to ensure accurate and reliable results, making it a trusted choice for patients seeking comprehensive CLL diagnostics.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PROGNOSTIC PANEL Test

Test Cost: AED 4210.0

Symptoms, Diagnosis, and Test Details

Chronic Lymphocytic Leukemia (CLL) is a type of cancer that affects the lymphocytes, a type of white blood cell. To determine the prognosis of patients with CLL, DNA Labs UAE offers the CLL Prognostic Panel Test. This diagnostic test analyzes specific genetic and molecular markers in the patient’s leukemia cells to predict the likelihood of disease progression and overall survival.

The CLL Prognostic Panel Test includes various markers:

  1. Immunoglobulin heavy chain variable region (IGHV) mutation status: This marker helps determine the aggressiveness of the disease. Patients with unmutated IGHV have a poorer prognosis compared to those with mutated IGHV.
  2. Zeta-chain-associated protein kinase 70 (ZAP-70) expression: ZAP-70 is a protein that is often overexpressed in aggressive forms of CLL. High levels of ZAP-70 indicate a higher risk of disease progression and poorer outcomes.
  3. CD38 expression: CD38 is a protein found on the surface of CLL cells. Higher levels of CD38 expression are associated with more aggressive disease and a poorer prognosis.
  4. FISH (fluorescence in situ hybridization) analysis: FISH testing detects specific genetic abnormalities in CLL cells, such as deletions or rearrangements of certain chromosomes. These abnormalities can provide additional information about the patient’s prognosis and guide treatment decisions.

The CLL Prognostic Panel Test helps doctors classify patients into different risk groups, such as low-risk, intermediate-risk, or high-risk, based on the likelihood of disease progression and overall survival. This information is valuable for determining the most appropriate treatment approach, including whether to initiate treatment immediately or adopt a watch-and-wait strategy.

It’s important to note that the CLL Prognostic Panel Test is just one tool among many used to assess CLL prognosis. Other factors, such as the patient’s age, overall health, and response to treatment, also play a role in determining the prognosis. Therefore, the test results should be interpreted in conjunction with other clinical and laboratory findings.

Test Components:

  • ZAP 70
  • CD38
  • CD49d
  • IGVH
  • del11q23(ATM)
  • del17p13.1(TP53)
  • del13q14.3
  • del13q34
  • Trisomy 12

Test Information:

  • Price: AED 4210.0
  • Sample Condition: 4 mL (2 mL min.) whole blood from 1 Lavender top (EDTA) tube AND 5 mL (3 mL min.) whole blood OR 4 mL ( 2 mL min.) Bone Marrow from 2 Green Top (Sodium Heparin) tubes. Ship at 18-22°C. DO NOT FREEZE.
  • Report Delivery: Sample Mon by 9 am; Report Next Mon
  • Method: PCR Sequencing, FISH, Flow cytometry
  • Test Type: Leukemia
  • Doctor: Hematologist, Oncologist
  • Test Department: MOLECULAR DIAGNOSTICS
  • Pre Test Information: Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory.
Test Name CHRONIC LYMPHOCYTIC LEUKEMIA CLL?ÿ PROGNOSTIC PANEL Test
Components *ZAP 70*CD38*CD49d*IGVH *del11q23(ATM)*del17p13.1(TP53) *del13q14.3*del13q34*Trisomy 12
Price 4210.0 AED
Sample Condition 4 mL (2 mL min.) whole blood from 1 Lavender top (EDTA) tube AND 5 mL (3 mL min.) whole blood OR 4 mL ( 2 mL min.) Bone Marrow from 2 Green Top (Sodium Heparin) tubes. Ship at 18-22?\u00f8C. DO NOT FREEZE. Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory.
Report Delivery SampleMon by 9 am; Report Next Mon
Method PCR Sequencing, FISH, Flow cytometry
Test type Leukemia
Doctor Hematologist, Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory.
Test Details

The CLL prognostic panel test is a diagnostic test used to determine the prognosis of patients with chronic lymphocytic leukemia (CLL). CLL is a type of cancer that affects the lymphocytes, a type of white blood cell.

The prognostic panel test analyzes specific genetic and molecular markers in the patient’s leukemia cells to predict the likelihood of disease progression and overall survival. It helps doctors tailor the treatment plan based on the patient’s individual risk profile.

The test typically includes various markers, such as:

1. Immunoglobulin heavy chain variable region (IGHV) mutation status: This marker helps determine the aggressiveness of the disease. Patients with unmutated IGHV have a poorer prognosis compared to those with mutated IGHV.

2. Zeta-chain-associated protein kinase 70 (ZAP-70) expression: ZAP-70 is a protein that is often overexpressed in aggressive forms of CLL. High levels of ZAP-70 indicate a higher risk of disease progression and poorer outcomes.

3. CD38 expression: CD38 is a protein found on the surface of CLL cells. Higher levels of CD38 expression are associated with more aggressive disease and a poorer prognosis.

4. FISH (fluorescence in situ hybridization) analysis: FISH testing detects specific genetic abnormalities in CLL cells, such as deletions or rearrangements of certain chromosomes. These abnormalities can provide additional information about the patient’s prognosis and guide treatment decisions.

The results of the CLL prognostic panel test help doctors classify patients into different risk groups, such as low-risk, intermediate-risk, or high-risk, based on the likelihood of disease progression and overall survival. This information is valuable for determining the most appropriate treatment approach, including whether to initiate treatment immediately or adopt a watch-and-wait strategy.

It’s important to note that the CLL prognostic panel test is just one tool among many used to assess CLL prognosis. Other factors, such as the patient’s age, overall health, and response to treatment, also play a role in determining the prognosis. Therefore, the test results should be interpreted in conjunction with other clinical and laboratory findings.

SKU: TEST-4661 Category:

Related products